AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab vs placebo. Mepolizumab was found to ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...
MedPage Today on MSN2d
FDA OKs New Option for Rare Immune-Mediated VasculitisEGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback